The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK , the Financial Times ...
After calling Rockville, Maryland, home for more than eight years, GSK's vaccine and infectious disease R&D teams are ...
The company, based in Dundee, Scotland, says it has already produced drug candidates for other clients in one quarter of the time normally needed. Exscientia and GSK aim to discover novel and ...
The incoming employees at the biopharmaceutical giant will zero in on mRNA, structural biology, and viral vaccine research ...
Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has bee ...
British drug maker GSK on Monday said it will buy US biopharmaceutical company IDRx for up to $1.15 billion. The Boston-based biotechnology firm is developing therapeutics for the treatment of ...
While J&J announced a big deal to acquire neuroscience company Intra-Cellular Therapies ITCI, Lilly and GSK announced smaller deals. The drug and medical devices giant entered into a definitive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback